Affiliation:
1. Department of Pharmacology and Therapeutics , Seth G.S. Medical College and KEM Hospital , Parel , Mumbai , India
Abstract
Abstract
IcoSema, a groundbreaking approach to diabetes management, combines insulin icodec and semaglutide to offer a transformative treatment option. Insulin icodec delivers consistent glucose-lowering effects with once-weekly dosing, while semaglutide, a GLP-1 agonist, stimulates insulin secretion and aids in weight loss. This comprehensive article evaluates the potential of IcoSema from a clinical pharmacology perspective, examining the pharmacokinetics, efficacy, safety, compliance and cost-effectiveness of its individual components, as well as considering comparable combination therapies like iGlarLixi and IDegLira. By analysing these crucial factors, the article aims to determine the potential of IcoSema in the field of diabetes management. The combination of insulin icodec and semaglutide has the potential to provide improved glycaemic control, weight management, and simplified treatment regimens, addressing common challenges faced in diabetes management. Safety, compliance and cost considerations are important aspects of evaluating this combination therapy. Ongoing trials investigating IcoSema are expected to provide valuable insights into its efficacy, safety and comparative effectiveness. By addressing concerns such as potential side effects, individual patient response and drug interactions, healthcare providers can optimize treatment outcomes and enhance the management of type 2 diabetes.
Reference43 articles.
1. Najafipour, H, Farjami, M, Sanjari, M, Amirzadeh, R, Shadkam Farokhi, M, Mirzazadeh, A. Prevalence and incidence rate of diabetes, pre-diabetes, uncontrolled diabetes, and their predictors in the adult population in southeastern Iran: findings from KERCADR study. Front Public Health 2021;9:611652. https://doi.org/10.3389/fpubh.2021.611652.
2. Committee ADAPP. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care 2022;45:S125–43. https://doi.org/10.2337/dc22-s009.
3. A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly insulin icodec - full text view - ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT05352815 [cited 2023 Jul 7].
4. Nishimura, E, Pridal, L, Glendorf, T, Hansen, BF, Hubálek, F, Kjeldsen, T, et al.. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care 2021;9:2301. https://doi.org/10.1136/bmjdrc-2021-002301.
5. Mahapatra, MK, Karuppasamy, M, Sahoo, BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord 2022;23:521. https://doi.org/10.1007/s11154-021-09699-1.